Zamira Raises $3.4M To Support Expansion Strategy
Henslow is pleased to announce that we have successfully assisted Zamira in raising $3.4M via a rights issue to existing and new investors.
Zamira is an Australian animal health brand whose mission is to improve the health, wellbeing and productivity of animals across the world. They are favourably positioned as a premium brand with localised understanding and expertise — a trusted and strong Australian brand identity amongst their international competitors. The company maintains a key manufacturing partnership with global leader Bioproton which enables speed-to-market and continued improvement of their product ranges.
Innovation and flexibility fuelled by consumer demand
These funds will be used to support working capital for the expansion into the ‘Companion Animal’ market — a rapidly growing multi-billion dollar product category – and strengthen the company’s balance sheet for future growth.
Led by a world-class executive team with a proven history of scaling multinational businesses from concept to A$1.7BN, Zamira’s goal is to become a global leader in the supply of animal health products.
Well-positioned with a strong foundation in a growing market
Stewart Cairns, CEO of Zamira, commented,
“Chris and the team at Henslow have facilitated a transformation of our business over the past 12-18 months; providing direction and support to simplify our capital structure, strengthen our board and attract key team members and professional investors, enabling us to pursue a growth plan that will deliver value to our shareholders.”
Henslow has partnered with Zamira since 2019, and looks forward to continuing to support the company with its growth plans.
Want to discuss this transaction further? Get in touch with the Henslow team below.